Business Context and Reporting Period
This Form 6-K filing by Immunocore Holdings Plc covers the month of September 2022. The report serves primarily to incorporate legal opinions by reference into the Company's registration statement on Form F-3ASR (File No. 333-264105) regarding the resale of American Depositary Shares (ADSs) by selling shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing for legal opinions and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this text. The filing updates the registration statement with new legal opinions dated September 30, 2022, superseding or supplementing previous documents related to the resale of ADSs.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The content is limited to the incorporation of legal opinions (Exhibits 5.1 and 5.2) and consents from Cooley (UK) LLP.
Investor Verification Checklist
- Verify the details of the selling shareholders identified in the prospectus supplement dated September 30, 2022.
- Review the full text of the legal opinions from Cooley (UK) LLP included as Exhibits 5.1 and 5.2.
- Confirm the status of the Form F-3ASR registration statement (File No. 333-264105) for the resale of ADSs.
- Note that this filing does not contain operational or financial results; refer to the Company's Form 20-F or quarterly reports for financial data.